Bristol Myers Squibb Company $BMY Stock Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lessened its position in Bristol Myers Squibb Company (NYSE:BMY) by 11.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 866,982 shares of the biopharmaceutical company’s stock after selling 108,592 shares during the period. Commonwealth Equity Services LLC’s holdings in Bristol Myers Squibb were worth $54,100,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in BMY. Kestra Private Wealth Services LLC increased its stake in shares of Bristol Myers Squibb by 0.7% in the third quarter. Kestra Private Wealth Services LLC now owns 152,101 shares of the biopharmaceutical company’s stock valued at $9,491,000 after buying an additional 1,071 shares in the last quarter. Costello Asset Management INC lifted its position in Bristol Myers Squibb by 20.0% during the 3rd quarter. Costello Asset Management INC now owns 1,200 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 200 shares in the last quarter. Optimist Retirement Group LLC grew its holdings in Bristol Myers Squibb by 1.7% during the 3rd quarter. Optimist Retirement Group LLC now owns 44,295 shares of the biopharmaceutical company’s stock worth $2,764,000 after acquiring an additional 753 shares during the last quarter. Richardson Financial Services Inc. grew its holdings in Bristol Myers Squibb by 9.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 3,845 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 320 shares during the last quarter. Finally, Verity Asset Management Inc. increased its position in Bristol Myers Squibb by 0.6% in the 3rd quarter. Verity Asset Management Inc. now owns 31,594 shares of the biopharmaceutical company’s stock valued at $1,971,000 after acquiring an additional 190 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $62.20 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The stock has a market capitalization of $127.15 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. The business has a 50-day moving average price of $62.34 and a two-hundred day moving average price of $60.11.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same quarter last year, the firm earned $1.63 EPS. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Equities analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Insiders Place Their Bets

In other news, Director Julia A. Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the transaction, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This represents a 11.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by insiders.

Analyst Ratings Changes

BMY has been the subject of a number of research analyst reports. Morgan Stanley dropped their target price on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research note on Friday, October 30th. Roth Capital began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Wednesday, August 5th. TD Cowen assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating on the stock. Finally, Zacks Research lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $65.46.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.